I'm surprised nobody's saying anything about the rumors about possible cardiovascular events for multiple myeloma patients taking Kyprolis? That's not helping, either. Yes, it could remove a competitor from the market, but it also means all that time to plan out a pathway to the market for ARRY-520 goes down the drain.
Or its a good buying opportunity, if you only buy stocks when they are green its going to be difficult to make money. I did my DD, researched the pipeline, and speculation over why Koch is out the door doesn't concern me as an investor.